Skip to main content
ACHIEVE LIFE SCIENCES, INC. logo

ACHIEVE LIFE SCIENCES, INC. — Investor Relations & Filings

Ticker · ACHV ISIN · US0044685008 LEI · 549300V82ZKZDTAU0A46 US Manufacturing
Open in API
Filings indexed 1,014 across all filing types
Latest filing 2008-12-05 Regulatory Filings
Country US United States of America
Listing US ACHV

About ACHIEVE LIFE SCIENCES, INC.

https://achievelifesciences.com/

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company dedicated to addressing the global nicotine dependence epidemic. The company's primary focus is the development and commercialization of its lead product candidate, cytisinicline, for smoking cessation. Following the successful completion of two Phase 3 studies, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which has been accepted for review. If approved, cytisinicline has the potential to become the first new FDA-approved treatment option for nicotine dependence in the United States in nearly two decades.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2008
Regulatory Filings Classification · 100% confidence The document is titled 'POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT' filed with the SEC. It is a post-effective amendment to a registration statement under the Securities Act of 1933, specifically Form S-3. The content discusses removing unsold securities from registration and includes signatures of officers and directors. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual report. This document is a regulatory filing related to securities registration and amendments, not a financial report or capital update. Therefore, it fits best under Regulatory Filings (RNS).
2008-12-05 English
Capital/Financing Update 2008
Capital/Financing Update Classification · 95% confidence The document is titled 'POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT' filed with the SEC. It is a post-effective amendment to a registration statement under the Securities Act of 1933, specifically Form S-3, which is used for registering securities offerings. The text discusses removing unsold securities from registration and includes signatures of officers and directors. This is clearly related to capital raising and securities registration activities, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual amendment filing, not just an announcement or certification. Confidence is high due to explicit references to Form S-3 and registration statement amendments.
2008-12-05 English
Regulatory Filings 2008
Regulatory Filings Classification · 100% confidence The document is titled 'POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT' filed with the SEC. It is a post-effective amendment to a registration statement under the Securities Act of 1933, specifically Form S-3. The content includes details about removing unsold securities from registration and signatures of officers and directors. There are no financial statements or detailed financial data present. The document is a regulatory filing related to securities registration and amendments, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS).
2008-12-05 English
Transaction in Own Shares 2008
Transaction in Own Shares Classification · 100% confidence The document is titled 'POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT' filed with the SEC. It discusses the removal of unsold shares from registration under various stock option and purchase plans that have terminated. The document is a formal amendment to a previously filed registration statement (Form S-8) related to stock option plans. It does not contain financial statements, earnings data, or management discussion. Instead, it is an update to a capital market filing concerning registration of securities. This type of filing corresponds to a Transaction in Own Shares (POS) category, which covers share repurchase or issuance related filings, including amendments to registration statements for stock plans.
2008-12-05 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 3, 2008. It primarily announces a press release about a clinical study result (OGX-011 shows survival advantage in prostate cancer). The document is short (2905 characters) and mainly serves as a regulatory filing to disclose material information promptly. It does not contain financial statements, detailed financial data, or comprehensive management discussion. It also explicitly states that the information is not "filed" for certain regulatory purposes and is incorporated by reference only. This matches the characteristics of a Regulatory Filing (RNS) rather than a full financial report or earnings release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2008-12-03 English
FORM 4/A SUBMISSION
Director's Dealing
2008-11-17 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.